Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Executive Summary
Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement
You may also be interested in...
Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr
Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28
Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr
Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28
Barr Patent Challenge Expenses Estimated At $200 Mil. Over Next Five Years
Barr expects to spend about $200 mil. in Paragraph IV patent challenges through 2007, CEO Bruce Downey told a recent Generic Pharmaceutical Association workshop in New York City